25/06/2020 : Theradiag: Combined General Meeting of shareholders of June 25, 2020 on second call – Voting results and resolutions

Croissy-Beaubourg, June 25, 2020 6:00 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, informs its shareholders that its Combined General Meeting was held on second call in closed session, without shareholders or other people allowed to assist being physically present, on Thursday 25 June 2020 at 2:00 pm at the Company’s registered office and chaired by Mr. Pierre Morgon, Chairman of the Board of Directors.

Following this Combined General Meeting held on second call, Theradiag informs its shareholders that the number of shares held by shareholders who voted by mail or by proxy was 2,006,369, representing a quorum of 23.218%.

Theradiag’s shareholders voted all the resolutions presented in the way recommended by the Board of Directors.

The Company wishes to sincerely thank all of its shareholders for their commitment to the voting process and for their support.

The detailed voting results by resolution at this Combined General Meeting are the following:

The minutes of this Combined General Meeting will be made available soon on the Company’s website (in French): https://www.theradiag.com/en/investors/shareholder-information/general-meeting/

***

Financial calendar:

  • H1 2020 revenue, Tuesday, July 21, 2020
  • H1 2020 results, Monday, September 21, 2020

 About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years. 

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.  For more information about Theradiag, please visit our website: www.theradiag.com

Theradiag

Bertrand de Castelnau

CEO/Managing Director

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Financial Communications & Investor Relations

Sandrine Boussard-Gallien

Claire Riffaud

Tel.: +33 (0)1 44 71 94 94

theradiag@newcap.eu

NewCap

Media Relations

Nicolas Mérigeau

Tel.: +33 (0)1 44 71 94 98

nmerigeau@newcap.fr